Immunome, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IMNM | IDYA | IMTX | IMCR | PYXS | IOVA | |
|---|---|---|---|---|---|---|
| Market cap | 2.26B | 3.48B | 1.10B | 1.50B | 240.11M | 6.60B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -7.9 | -9.0 | -3.5 | -38.5 | -1.8 | -67.9 |
| Price/book | 4.1 | 2.9 | 2.2 | 3.6 | 11.2 | 9.0 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +35.82% | +33.21% | −29.11% | −8.45% | −37.77% | +586.79% |
| Today | −2.05% | −0.14% | −2.96% | −1.19% | −0.99% | −0.41% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IMNM news ›Arbutus Biopharma (NASDAQ:ABUS) vs. Immunome (NASDAQ:IMNM) Financial Comparison
Posted by Michael Walen on Oct 12th, 2026 Immunome (NASDAQ:IMNM – Get Free Report) and Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Immunome (NASDAQ:IMNM) Stock Price Down 6.6% – What’s Next?
Posted by Michael Walen on Oct 8th, 2026 Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares dropped 6.6% during mid-day trading on Tuesday. The company traded as low as $19.84 and last traded at $19.7820. Approximately 448,182 shares…
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 6, 2026
BioSpace Each stock option has an exercise price per share equal to $20.89, the Company’s closing sales price on October 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the…
Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
TradingView Immunome - Enters Amendment No. 4 To License Agreement With Bristol-Myers Squibb Company On Oct 2, 2026
FDA clears Immunome to test a cancer drug in people; a study is expected in the fourth quarter of 2026.
IM-1340 becomes Immunome’s fifth program in clinical development, with a first-in-human study expected in the fourth quarter of 2026. Sentiment and the balance of points Rhea-AI Sentiment reads the wording of the document, how positive or…
Immunome (IMNM) Gains FDA IND Clearance for IM-1340 Targeting Ad
On September 30, 2026, Immunome Inc (NASDAQ: IMNM) announced that the U.S. Food and Drug Administration has authorized its Investigational New Drug (IND) application for IM-1340, a novel antibody-drug conjugate designed to treat advanced…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net2
-
themarketsdaily.com2
-
biospace.com1
-
gurufocus.com1
-
tradingview.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.